# Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

> **NCT05620134** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Salubris Biotherapeutics Inc** · enrollment: 263 (estimated)

## Conditions studied

- Cancer
- Tumor, Solid
- Advanced Solid Tumor
- Metastatic Cancer
- Melanoma
- Colorectal Cancer
- Non-small Cell Lung Cancer
- Small-cell Lung Cancer
- Urothelial Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Luminal Breast Cancer
- Triple Negative Breast Cancer
- Clear Cell Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- Gastric Adenocarcinoma
- GastroEsophageal Cancer
- Squamous Cell Carcinoma Skin
- Pancreatic Adenocarcinoma
- Hepatocellular Carcinoma
- Colorectal Adenocarcinoma
- Epithelial Ovarian Cancer
- Thyroid Cancer

## Interventions

- **DRUG:** JK08
- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib Pill

## Key facts

- **NCT ID:** NCT05620134
- **Lead sponsor:** Salubris Biotherapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-17
- **Primary completion:** 2025-10-17
- **Final completion:** 2026-02-20
- **Target enrollment:** 263 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05620134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05620134, "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05620134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*